Hizentra Market Report 2026: Epidemiology, Pipeline Analysis, Market Insights & Forecasts

The growth in the historic period can be attributed to limitations of ivig hospital based therapy, increasing prevalence of primary immunodeficiency, clinical success of scig therapies, demand for home care options, improved patient adherence.

The growth in the forecast period can be attributed to growth in home healthcare services, increasing diagnosis of immune disorders, expansion of long term replacement therapy demand, technological advances in infusion devices, supportive reimbursement for scig. Major trends in the forecast period include shift toward subcutaneous immunoglobulin therapy, growth of home based immunodeficiency treatment, preference for flexible and self administered dosing, expansion of long term immunoglobulin replacement, rising focus on patient quality of life.

The increasing prevalence of autoimmune disorders is expected to accelerate the growth of the Hizentra market. Autoimmune disorders occur when the immune system mistakenly attacks the body's own healthy cells, tissues, or organs. The rise in autoimmune disorders is attributed to a combination of genetic, environmental, and lifestyle factors, including increased environmental toxins, dietary changes, and reduced exposure to pathogens. Hizentra is used in the treatment of autoimmune disorders to provide immunoglobulin replacement therapy, which helps regulate immune system activity and alleviate disease symptoms. For example, in May 2023, the NIHR Imperial Biomedical Research Centre, a UK-based government research institute, analyzed anonymized electronic health records from 22 million UK individuals to examine 19 common autoimmune diseases, which affect about 10% of the population - 13% of women and 7% of men. As a result, the rise in autoimmune disorders is driving the growth of the Hizentra market.

The rising healthcare expenditure is also expected to drive the growth of the Hizentra market. Healthcare expenditure refers to the total resources allocated to healthcare services, products, and activities, including prevention, diagnosis, treatment, and management of health conditions. Healthcare spending is increasing due to factors such as an aging population, advancements in medical technology, the growing prevalence of chronic diseases, and rising costs of pharmaceuticals and medical services. Increased healthcare expenditure improves the accessibility and affordability of Hizentra, supporting the treatment of patients with primary immunodeficiency and other conditions. For instance, in May 2024, the Office for National Statistics, a UK-based government department, reported a 5.6% increase in total healthcare expenditure from 2022 to 2023, marking a significant acceleration compared to the 0.9% growth in 2022. As such, the rise in healthcare expenditure is driving the growth of the Hizentra market.

A key trend in the Hizentra market is the focus on developing innovative products, such as prefilled syringes, to gain a competitive edge in the industry. A prefilled syringe is a single-use device prefilled with a specific dose of medication, ensuring accurate dosing and reducing preparation time. Typically made from glass or plastic, these syringes are designed for ease of use in both self-administration and clinical settings. For example, in April 2023, CSL Behring, a U.S.-based biotechnology company, announced that the U.S. Food and Drug Administration (FDA) approved a new 50 mL/10 g prefilled syringe for Hizentra (immune globulin subcutaneous [human] 20% Liquid). With this new addition, CSL Behring now offers a full range of prefilled syringe sizes to meet the unique needs of individuals with primary immunodeficiency (PI) or chronic inflammatory demyelinating polyneuropathy (CIDP). Hizentra is the first and only immune globulin (Ig) available in a ready-to-administer prefilled syringe format, offering greater convenience and ease of use.

Major companies operating in the hizentra market are CSL Behring.

North America was the largest region in the hizentra market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the hizentra market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hizentra market report are Australia, India, China, South Korea, Japan, UK, France, Germany, USA, Canada.

Tariffs have impacted the hizentra market by increasing costs related to plasma derived raw materials, fractionation equipment, and cold chain logistics. These effects are most pronounced for hospitals and home healthcare providers in regions reliant on imported immunoglobulin products. Higher tariffs may influence therapy pricing and reimbursement dynamics. However, tariffs are encouraging domestic plasma collection and processing investments. This supports long term supply security for immunoglobulin therapies.

The hizentra market research report is one of a series of new reports that provides hizentra market statistics, including hizentra industry global market size, regional shares, competitors with a hizentra market share, detailed hizentra market segments, market trends and opportunities, and any further data you may need to thrive in the hizentra industry. This hizentra market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Hizentra is a brand of subcutaneous immunoglobulin (SCIg) therapy used to treat patients with primary immunodeficiencies, such as common variable immunodeficiency (CVID), and certain other immune-related conditions. It contains immunoglobulin G (IgG), a protein that aids the immune system in fighting infections. Hizentra is administered subcutaneously, providing an alternative to intravenous immunoglobulin (IVIg) therapy, and is typically used to enhance the body’s immune defense in individuals with compromised immune systems. The medication is known for offering more flexible dosing options and potentially greater convenience compared to traditional IV-based therapies.

The primary product types of Hizentra are subcutaneous immunoglobulin (SCIg) and intravenous immunoglobulin (IVIg). Subcutaneous immunoglobulin (SCIg) is a form of immunoglobulin therapy administered under the skin to boost the immune system in patients with immune deficiencies. It is used for primary immunodeficiency (PI) and chronic inflammatory demyelinating polyneuropathy (CIDP) and is distributed through various channels, including hospitals, specialty pharmacies, home healthcare providers, and retail pharmacies.

The hizentra market consists of sales of coagulation factor concentrates, albumin solutions, hyperimmune immunoglobulins, and cryoprecipitate. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.